PCN85 SORAFENIB AND SUNITINIB IN METASTATIC RENAL CELL CARCINOMA: COST-EFFECTIVENESS ANALYSIS IN REIMBURSEMENT PROCEEDINGS VS. DATA FROM CLINICAL PRACTICE

Value in Health ◽

10.1016/s1098-3015(11)71980-5 ◽

2010 ◽

Vol 13 (7) ◽

pp. A267 ◽

Author(s):

B Ondrackova ◽

R Demlova

Keyword(s):

Renal Cell Carcinoma ◽

Clinical Practice ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness Analysis of Sunitinib and Sorafenib Sequential Treatment of Metastatic Renal Cell Carcinoma

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) ◽

10.5649/jjphcs.43.610 ◽

2017 ◽

Vol 43 (11) ◽

pp. 610-618

Author(s):

Toshihiro Shida ◽

Tomoyuki Kato ◽

Norihiko Tsuchiya ◽

Tadashi Shiraishi ◽

Tadao Inoue

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Sequential Treatment ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Using Everolimus or Axitinib in Patients with Metastatic Renal Cell Carcinoma WHO Have Failed to Use of Pazopanib or Sunitinib in First-Line Treatment

Value in Health ◽

10.1016/j.jval.2016.09.2223 ◽

2016 ◽

Vol 19 (7) ◽

pp. A735 ◽

Author(s):

ME Romero Prada ◽

LM Huerfano ◽

NC Roa Cardenas

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN127 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED WITH CURRENTLY AVAILABLE FIRST-LINE TREATMENTS IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC RENAL CELL CARCINOMA IN THE UNITED STATES

Value in Health ◽

10.1016/j.jval.2019.04.251 ◽

2019 ◽

Vol 22 ◽

pp. S80

Author(s):

N. Tanova ◽

S. Yang ◽

L.H. Cheung ◽

V. Genestier ◽

K.M. Gooden ◽

...

Keyword(s):

United States ◽

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

The United States ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

PCN169 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE

Value in Health ◽

10.1016/j.jval.2019.09.365 ◽

2019 ◽

Vol 22 ◽

pp. S468-S469

Author(s):

F. Diamantogiannis ◽

P. Viktoratos ◽

J. May ◽

B. Malcolm ◽

Van de Wetering G ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN13 COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN COLOMBIA (ONCOLGROUP STUDY)

Value in Health ◽

10.1016/s1098-3015(10)75340-7 ◽

2009 ◽

Vol 12 (7) ◽

pp. A495 ◽

Author(s):

JI Godoy ◽

AF Cardona ◽

HA Caceres ◽

JM Otero ◽

M Lujan ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Comparing Modeling Approaches In Cost-Effectiveness Analysis Using Secondary Survival Data: A Study of Nivolumab Versus Everolimus In The Treatment of Metastatic Renal Cell Carcinoma

Value in Health ◽

10.1016/j.jval.2016.03.654 ◽

2016 ◽

Vol 19 (3) ◽

pp. A79-A80 ◽

Author(s):

S. Grewal

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Survival Data ◽

Cost Effectiveness Analysis ◽

Modeling Approaches ◽

Effectiveness Analysis

Download Full-text

PCN77 COST-EFFECTIVENESS ANALYSIS OF TEMSIROLIMUS VS. SUNITINIB MALATE IN POOR PROGNOSIS METASTATIC RENAL CELL CARCINOMA (MRCC) IN PORTUGAL

Value in Health ◽

10.1016/s1098-3015(10)74328-x ◽

2009 ◽

Vol 12 (7) ◽

pp. A271 ◽

Author(s):

NM Silverio ◽

S Yang ◽

E Alemao

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Poor Prognosis ◽

Cost Effectiveness Analysis ◽

Sunitinib Malate ◽

Effectiveness Analysis

Download Full-text

PCN62 Cost-Effectiveness Analysis of First-Line Treatment for Metastatic Renal Cell Carcinoma in Colombia

Value in Health ◽

10.1016/j.jval.2012.03.1179 ◽

2012 ◽

Vol 15 (4) ◽

pp. A219

Author(s):

S.M. Nuñez ◽

J.I. Godoy ◽

A.F. Cardona ◽

J.M. Otero ◽

M. Lujan ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma

Frontiers in Pharmacology ◽

10.3389/fphar.2020.00619 ◽

2020 ◽

Vol 11 ◽

Author(s):

Peiyao Lu ◽

Weiting Liang ◽

Jiahao Li ◽

Yanming Hong ◽

Zhuojia Chen ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Effectiveness Analysis

Download Full-text

A Cost‐Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First‐Line Intermediate‐ to Poor‐Risk Advanced Renal Cell Carcinoma

The Oncologist ◽

10.1634/theoncologist.2018-0656 ◽

2019 ◽

Vol 24 (3) ◽

pp. 366-371 ◽

Author(s):

Daniel Reinhorn ◽

Michal Sarfaty ◽

Moshe Leshno ◽

Assaf Moore ◽

Victoria Neiman ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Poor Risk ◽

Effectiveness Analysis

Download Full-text